Trümper L, Pfreundschuh M
Klinik für Innere Medizin I [Homburg/Saar], Universitätskliniken des Saarlandes.
Ther Umsch. 1996 Feb;53(2):133-9.
High grade non-Hodgkin's lymphomas comprise a group of heterogenous disorders of the lymphatic system with aggressive clinical behaviour. Extranodal disease manifestations are common, especially in immunocompromised patients [e.g. AIDS]. High-grade NHL are chemo- and radiosensitive. Anthracyclin-containing chemotherapy regimens have led to a significant improvement in prognosis. The CHOP-regime, consisting of doxorubicin, cyclophosphamide, oncovin and prednisolon, is the standard therapy that should be given outside of clinical trials. Age, bad performance status, elevated serum-LDH, presence of more than one extranodal manifestation and disease stage III or IV have been defined as clinically relevant prognostic factors. Current treatment strategies include dose intensification by interval shortening and dose escalation as well as high-dose chemotherapy, followed by autologous stem cell rescue. Patients receiving these experimental therapies should be treated within multicenter clinical trials.
高级别非霍奇金淋巴瘤是一组具有侵袭性临床行为的淋巴系统异质性疾病。结外病变表现常见，尤其在免疫功能低下的患者中（如艾滋病患者）。高级别非霍奇金淋巴瘤对化疗和放疗敏感。含蒽环类药物的化疗方案已使预后有显著改善。由多柔比星、环磷酰胺、长春新碱和泼尼松龙组成的CHOP方案是临床试验之外应采用的标准疗法。年龄、体能状态差、血清乳酸脱氢酶升高、存在不止一处结外表现以及疾病分期为III期或IV期已被定义为临床相关的预后因素。当前的治疗策略包括通过缩短间隔和增加剂量来强化剂量，以及大剂量化疗，随后进行自体干细胞救援。接受这些实验性疗法的患者应在多中心临床试验中接受治疗。
